Summit Therapeutics rises as new ivonescimab brain-metastases data fuels FDA-event run-up
SMMT•Summit Therapeutics shares rose after it highlighted new Phase III ivonescimab lung-cancer data tied to brain-metastases control and the stock’s upcoming FDA decision timeline. Investors are also positioning ahead of the European Lung Cancer Congress presentations following the FDA’s accepted BLA with a November 14, 2026 PDUFA goal date.
1) What’s moving the stock today
Summit Therapeutics (SMMT) is trading higher as investors react to fresh attention on ivonescimab’s Phase III profile in advanced non-small cell lung cancer (NSCLC), including outcomes in patients with baseline brain metastases, and a clearer U.S. regulatory timeline. The latest catalyst is a renewed data-and-regulatory setup into the 2026 European Lung Cancer Congress (ELCC 2026) and the company’s pending FDA decision window.
2) The data focus: brain metastases and intracranial control
Ahead of ELCC 2026, Summit said Phase III HARMONi trial analyses will be presented, including intracranial efficacy results in EGFR TKI–resistant, EGFR-mutated NSCLC patients with and without asymptomatic brain metastases at baseline. A widely circulated summary of the announcement highlighted intracranial progression-free survival of 10.1 months for ivonescimab plus chemotherapy versus 6.5 months for chemotherapy in patients with baseline brain metastases (hazard ratio 0.53; nominal p=0.0068), putting brain-metastases control back at the center of the ivonescimab narrative.




